Research is ongoing to develop GABAergic drugs with fewer side effects and a lower potential for abuse. Novel compounds that selectively target specific subtypes of the GABA-A receptor are being investigated to provide therapeutic benefits without the drawbacks associated with current medications.
In conclusion, while GABAergic drugs play a crucial role in managing various CNS disorders, their toxicological profile necessitates careful consideration. Understanding their mechanisms, risks, and management strategies is essential for minimizing adverse outcomes and optimizing therapeutic efficacy.
